Aviceda Therapeutics
PrivateLast Round
Series C
Jan 7, 2025
Total Funding Raised
$211.75M
Company Overview
Aviceda Therapeutics is a biotechnology company that develops next-generation immunomodulators using its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform to address chronic, non-resolving inflammation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aviceda Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Aviceda Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 7, 2025 | ||||
| VC Round | May 31, 2024 | ||||
| VC Round | May 19, 2023 | ||||
| VC Round | Mar 28, 2022 | ||||
| Seed | Sep 16, 2020 |
Key People
Founding team and executive leadership
Aviceda Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series C, VC Round |
| Enavate Sciences | Series C, VC Round |
| Aberdeen Group plc | Series C |
| TCG Crossover | Series C, VC Round |
| Omega Funds | Series C, VC Round |
| Digitalis Ventures | Series C, VC Round |
| Blue Owl Capital | Series C, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2025
Dr. Emmett T. Cunningham, Jr. joins the board.
- Jan 8, 2025
AVD-104 is a clinical-stage candidate for geographic atrophy.
Aviceda Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aviceda Therapeutics's valuation, stock price, and market status.